|The Slc19a1 slc19a1 (Catalog #MBS340545) is an Antibody produced from Sheep and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Methotrexate can be used in a range of immunoassay formats including, but not limited to, ELISA, Western Blot, Dot Blot, Immunohistochemistry, Immunoassays, Development of Rapid tests and other immunoassay,antibody recognition assays. Researchers should empirically determine the suitability of the Slc19a1 slc19a1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The Slc19a1 slc19a1 product has the following accession number(s) (GI #5733102) (NCBI Accession #AAD49426.1) (Uniprot Accession #Q62866). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Methotrexate (rINN) abbreviated MTX and formerly known as amethopterin, is an antimetabolite and antifolate drug used in treatment of cancer, autoimmune diseases and as an abortifacient in the induction of medical abortions. It acts by inhibiting the metabolism of folic acid. Methotrexate competitively inhibits dihydrofolate reductase (DHFR), an enzyme that participates in the tetrahydrofolate synthesis. The affinity of methotrexate for DHFR is about one thousand-fold that of folate for DHFR. Methotrexate acts specifically during DNA and RNA synthesis, and thus it is cytotoxic during the S-phase of the cell cycle. Logically, it therefore has a greater toxic effect on rapidly dividing cells which replicate their DNA more frequently, and thus inhibits the growth and proliferation of these non-cancerous cells. Lower doses of methotrexate have been shown to be very effective for the management of rheumatoid arthritis, Crohn\'s disease, and psoriasis.
Immunogen: Methotrexate-BSA. Buffer: 20mM Phosphate, 150mM Sodium Chloride
Preservative: 0.09% Sodium Azide. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Slc19a1 are readily searchable from our website. Different antibodies against the same target such as Slc19a1 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. The following patways have been known to be associated with this gene. Brain, Embryonic Tissue, Eye, Heart, Kidney, Pancreas, Spleen, Thymus tissues are correlated with this protein.